Allen C Gao

List of Publications by Year
in descending order

123 papers	8,161 citations	38660 50 h-index	53109 85 g-index
124 all docs	124 docs citations	124 times ranked	10837 citing authors

#	Article	IF	Citations
1	Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene, 2003, 22, 319-329.	2.6	510
2	Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene, 2004, 23, 3550-3560.	2.6	487
3	Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Translational Andrology and Urology, 2015, 4, 365-80.	0.6	310
4	Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2014, 20, 3198-3210.	3.2	294
5	Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. Journal of the National Cancer Institute, 2017, 109, .	3.0	288
6	Interleukin-6 induces prostate cancer cell growth accompanied by activation of Stat3 signaling pathway. , 2000, 42, 239-242.		228
7	Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer. Cancer Research, 2015, 75, 1413-1422.	0.4	207
8	MicroRNA let-7c Suppresses Androgen Receptor Expression and Activity via Regulation of Myc Expression in Prostate Cancer Cells. Journal of Biological Chemistry, 2012, 287, 1527-1537.	1.6	171
9	Aberrant Activation of the Androgen Receptor by NF-Î²B2/p52 in Prostate Cancer Cells. Cancer Research, 2010, 70, 3309-3319.	0.4	165
10	MicroRNA let-7c Is Downregulated in Prostate Cancer and Suppresses Prostate Cancer Growth. PLoS ONE, 2012, 7, e32832.	1.1	163
11	NF-Î²B2/p52 Induces Resistance to Enzalutamide in Prostate Cancer: Role of Androgen Receptor and Its Variants. Molecular Cancer Therapeutics, 2013, 12, 1629-1637.	1.9	162
12	Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. Nature Genetics, 2005, 37, 407-412.	9.4	156
13	ROR-Î³ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. Nature Medicine, 2016, 22, 488-496.	15.2	155
14	Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clinical Cancer Research, 2003, 9, 370-6.	3.2	155
15	Stat3 activation in prostatic carcinomas. Prostate, 2002, 51, 241-246.	1.2	132
16	Stat3 activation of NF-ÂB p100 processing involves CBP/p300-mediated acetylation. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7264-7269.	3.3	126
17	Histone Methyltransferase NSD2/MMSET Mediates Constitutive NF-Î²B Signaling for Cancer Cell Proliferation, Survival, and Tumor Growth via a Feed-Forward Loop. Molecular and Cellular Biology, 2012, 32, 3121-3131.	1.1	123
18	Prostate Specific Antigen Expression Is Down-Regulated by Selenium through Disruption of Androgen Receptor Signaling. Cancer Research, 2004, 64, 19-22.	0.4	119

#	Article	IF	Citations
19	NF-ÎºB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer. Molecular Cancer Therapeutics, 2015, 14, 1884-1895.	1.9	108
20	Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. European Urology, 2018, 73, 715-723.	0.9	105
21	Molecular mechanisms of castration-resistant prostate cancer progression. Future Oncology, 2009, 5, 1403-1413.	1.1	100
22	Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer. Molecular Cancer Therapeutics, 2017, 16, 35-44.	1.9	100
23	Functional p53 determines docetaxel sensitivity in prostate cancer cells. Prostate, 2013, 73, 418-427.	1.2	99
24	Inhibition of ABCB1 Expression Overcomes Acquired Docetaxel Resistance in Prostate Cancer. Molecular Cancer Therapeutics, 2013, 12, 1829-1836.	1.9	97
25	Interleukin-6 Regulates Androgen Synthesis in Prostate Cancer Cells. Clinical Cancer Research, 2009, 15, 4815-4822.	3.2	92
26	RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells. Prostate, 2004, 60, 303-309.	1.2	89
27	Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition. Prostate, 2015, 75, 1341-1353.	1.2	87
28	Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer. Oncotarget, 2016, 7, 32210-32220.	0.8	87
29	Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Prostate, 2007, 67, 764-773.	1.2	85
30	Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells. Prostate, 2014, 74, 201-209.	1.2	83
31	Quercetin Targets hnRNPA1 to Overcome Enzalutamide Resistance in Prostate Cancer Cells. Molecular Cancer Therapeutics, 2017, 16, 2770-2779.	1.9	81
32	Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway. Prostate, 2004, 60, 178-186.	1.2	79
33	Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA). Prostate, 2006, 66, 1070-1075.	1.2	78
34	KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC. Oncogene, 2019, 38, 17-32.	2.6	77
35	Hypoxia Increases Androgen Receptor Activity in Prostate Cancer Cells. Cancer Research, 2006, 66, 5121-5129.	0.4	73
36	Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer. Nature Communications, 2018, 9, 4700.	5.8	71

#	Article	IF	Citations
37	Androgen receptor signaling intensity is a key factor in determining the sensitivity of prostate cancer cells to selenium inhibition of growth and cancer-specific biomarkers. Molecular Cancer Therapeutics, 2005, 4, 1047-1055.	1.9	67
38	Stat3 enhances transactivation of steroid hormone receptors. Nuclear Receptor, 2003, 1, 3.	10.0	66
39	Sanguinarine Suppresses Prostate Tumor Growth and Inhibits Survivin Expression. Genes and Cancer, 2010, 1, 283-292.	0.6	66
40	MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 531-538.	2.0	66
41	Selective Activation Of Members Of The Signal Transducers And Activators Of Transcription Family In Prostate Carcinoma. Journal of Urology, 2002, 167, 1859-1862.	0.2	64
42	Andrographolide, an Herbal Medicine, Inhibits Interleukin-6 Expression and Suppresses Prostate Cancer Cell Growth. Genes and Cancer, 2010, 1, 868-876.	0.6	64
43	Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer. Science Translational Medicine, 2019, 11, .	5.8	63
44	Inhibition of Stat3 activation by sanguinarine suppresses prostate cancer cell growth and invasion. Prostate, 2012, 72, 82-89.	1.2	62
45	Interleukinâ€6 induces neuroendocrine differentiation (NED) through suppression of REâ€1 silencing transcription factor (REST). Prostate, 2014, 74, 1086-1094.	1.2	62
46	Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway. Oncogene, 2003, 22, 7981-7988.	2.6	61
47	Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2. Molecular Cancer Therapeutics, 2009, 8, 665-671.	1.9	59
48	Requirement for NF-ÎºB in interleukin-4-induced androgen receptor activation in prostate cancer cells. Prostate, 2005, 64, 160-167.	1.2	58
49	Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer. Clinical Cancer Research, 2015, 21, 4133-4142.	3.2	57
50	Selenium Disrupts Estrogen Signaling by Altering Estrogen Receptor Expression and Ligand Binding in Human Breast Cancer Cells. Cancer Research, 2005, 65, 3487-3492.	0.4	55
51	Effect of the Specific Src Family Kinase Inhibitor Saracatinib on Osteolytic Lesions Using the PC-3 Bone Model. Molecular Cancer Therapeutics, 2010, 9, 1629-1637.	1.9	52
52	Targeting molecular resistance in castration-resistant prostate cancer. BMC Medicine, 2015, 13, 206.	2.3	52
53	Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer. Molecular Cancer Therapeutics, 2017, 16, 1521-1530.	1.9	52
54	AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer. Molecular Cancer Therapeutics, 2019, 18, 1875-1886.	1.9	51

#	Article	IF	Citations
55	ABCB1 Mediates Cabazitaxelâ€“Docetaxel Cross-Resistance in Advanced Prostate Cancer. Molecular Cancer Therapeutics, 2017, 16, 2257-2266.	1.9	49
56	Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies. American Journal of Clinical and Experimental Urology, 2015, 3, 64-76.	0.4	49
57	Prostate-Specific Antigen Modulates Genes Involved in Bone Remodeling and Induces Osteoblast Differentiation of Human Osteosarcoma Cell Line SaOS-2. Clinical Cancer Research, 2006, 12, 1420-1430.	3.2	48
58	Stat3 enhances the growth of LNCaP human prostate cancer cells in intact and castrated male nude mice. Prostate, 2002, 52, 123-129.	1.2	47
59	NFâ€ÎºB2/p52 enhances androgenâ€independent growth of human LNCaP cells via protection from apoptotic cell death and cell cycle arrest induced by androgenâ€deprivation. Prostate, 2008, 68, 1725-1733.	1.2	45
60	Mechanisms of selenium down-regulation of androgen receptor signaling in prostate cancer. Molecular Cancer Therapeutics, 2006, 5, 913-918.	1.9	42
61	Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives. World Journal of Urology, 2012, 30, 287-295.	1.2	42
62	Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer. Molecular Cancer Therapeutics, 2020, 19, 1708-1718.	1.9	42
63	Suppression of the tumorigenicity of prostatic cancer cells by gene(s) located on human chromosome 19p13.1-13.2. , 1999, 38, 46-54.		40
64	Developmental and androgenic regulation of chromatin regulators EZH2 and ANCCA/ATAD2 in the prostate Via MLL histone methylase complex. Prostate, 2013, 73, 455-466.	1.2	40
65	The Androgen Receptor in Prostate Cancer: Effect of Structure, Ligands and Spliced Variants on Therapy. Biomedicines, 2020, 8, 422.	1.4	40
66	Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter. Molecular Cancer Therapeutics, 2007, 6, 2572-2580.	1.9	38
67	Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells. Prostate, 2008, 68, 85-91.	1.2	38
68	Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer. Scientific Reports, 2021, 11, 6377.	1.6	38
69	Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy. Cancers, 2017, 9, 9.	1.7	37
70	MicroRNAâ€181a promotes docetaxel resistance in prostate cancer cells. Prostate, 2017, 77, 1020-1028.	1.2	35
71	Upregulation of glucose metabolism by NF-ÎºB2/p52 mediates enzalutamide resistance in castration-resistant prostate cancer cells. Endocrine-Related Cancer, 2014, 21, 435-442.	1.6	34
72	Effects of Triclocarban on Intact Immature Male Rat: Augmentation of Androgen Action. Reproductive Sciences, 2011, 18, 119-127.	1.1	33

#	Article	IF	Citations
73	Microarray analysis reveals potential target genes of NFâ€ºB2/p52 in LNCaP prostate cancer cells. Prostate, 2010, 70, 276-287.	1.2	32
74	Andrographolide Targets Androgen Receptor Pathway in Castration-Resistant Prostate Cancer. Genes and Cancer, 2011, 2, 151-159.	0.6	32
75	LNCaP prostate cancer cells with autocrine interleukinâ€6 expression are resistant to ILâ€6â€induced neuroendocrine differentiation due to increased expression of suppressors of cytokine signaling. Prostate, 2012, 72, 1306-1316.	1.2	31
76	WLS-Wnt signaling promotes neuroendocrine prostate cancer. IScience, 2021, 24, 101970.	1.9	31
77	Mechanisms of selenium chemoprevention and therapy in prostate cancer. Molecular Nutrition and Food Research, 2008, 52, 1247-1260.	1.5	30
78	Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer. Molecular Cancer Therapeutics, 2018, 17, 2197-2205.	1.9	30
79	LIGHT, a member of the TNF superfamily, activates Stat3 mediated by NIK pathway. Biochemical and Biophysical Research Communications, 2007, 359, 379-384.	1.0	29
80	Interleukinâ€4 activates androgen receptor through CBP/p300. Prostate, 2009, 69, 126-132.	1.2	29
81	Lin28 Promotes Growth of Prostate Cancer Cells and Activates the Androgen Receptor. American Journal of Pathology, 2013, 183, 288-295.	1.9	29
82	Induction of neuroendocrine differentiation in castration resistant prostate cancer cells by adipocyte differentiation-related protein (ADRP) delivered by exosomes. Cancer Letters, 2017, 391, 74-82.	3.2	29
83	Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patientâ€derived, advanced prostate cancer tissue xenograft model. Molecular Oncology, 2014, 8, 311-322.	2.1	28
84	Intracellular glutathione content influences the sensitivity of lung cancer cell lines to methylseleninic acid. Molecular Carcinogenesis, 2012, 51, 303-314.	1.3	26
85	Germline and somatic DNA repair gene alterations in prostate cancer. Cancer, 2020, 126, 2980-2985.	2.0	24
86	Microarray Data Mining for Potential Selenium Targets in Chemoprevention of Prostate Cancer. Cancer Genomics and Proteomics, 2005, 2, 97-114.	1.0	23
87	Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells. Endocrinology, 2017, 158, 2255-2268.	1.4	22
88	Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer. Translational Oncology, 2019, 12, 871-878.	1.7	22
89	Lin28 induces resistance to antiâ€androgens via promotion of AR splice variant generation. Prostate, 2016, 76, 445-455.	1.2	20
90	Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer. Asian Journal of Urology, 2016, 3, 185-194.	0.5	20

#	Article	IF	Citations
91	A Circulating Tumor Cell-RNA Assay for Assessment of Androgen Receptor Signaling Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer. Theranostics, 2019, 9, 2812-2826.	4.6	20
92	Current strategies for targeting the activity of androgen receptor variants. Asian Journal of Urology, 2019, 6, 42-49.	0.5	18
93	Therapeutic Targeting of MDR1 Expression by RORÎ³ Antagonists Resensitizes Cross-Resistant CRPC to Taxane via Coordinated Induction of Cell Death Programs. Molecular Cancer Therapeutics, 2020, 19, 364-374.	1.9	18
94	Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostate. BJU International, 2022, 129, 345-355.	1.3	18
95	The interleukin 6 receptor is a direct transcriptional target of E2F3 in prostate tumor derived cells. Prostate, 2012, 72, 649-660.	1.2	17
96	Expression of homeobox gene-GBX2 in human prostatic cancer cells. , 1996, 29, 395-398.		16
97	Defining regulatory elements in the humanKAI1 (CD 82) metastasis suppressor gene. Prostate, 2003, 57, 256-260.	1.2	16
98	Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line. Prostate, 2007, 67, 1293-1300.	1.2	16
99	Novel nomograms for castrationâ€resistant prostate cancer and survival outcome in patients with de novo bone metastatic prostate cancer. BJU International, 2018, 122, 994-1002.	1.3	16
100	Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer. Clinical Cancer Research, 2020, 26, 6064-6074.	3.2	16
101	ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling. Oncogene, 2021, 40, 5379-5392.	2.6	16
102	RhoGDIÎ± suppresses growth and survival of prostate cancer cells. Prostate, 2012, 72, 392-398.	1.2	15
103	What kind of patients with castration-naÃ¯ve prostate cancer can benefit from upfront docetaxel and abiraterone: A systematic review and a network meta-analysis. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 505-517.	0.8	11
104	GnRH Antagonists Have Direct Inhibitory Effects On Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression. Molecular Cancer Therapeutics, 2019, 18, 1811-1821.	1.9	11
105	IFNÎ³, a Double-Edged Sword in Cancer Immunity and Metastasis. Cancer Research, 2019, 79, 1032-1033.	0.4	11
106	Activation of the ABCB1 Amplicon in Docetaxel- and Cabazitaxel-Resistant Prostate Cancer Cells. Molecular Cancer Therapeutics, 2021, 20, 2061-2070.	1.9	10
107	CCN3-EZH2-AR feedback loop: new targets for enzalutamide and castration resistant prostate cancer. Journal of Cell Communication and Signaling, 2017, 11, 89-91.	1.8	9
108	Bidirectional Cross-talk between MAOA and AR Promotes Hormone-Dependent and Castration-Resistant Prostate Cancer. Cancer Research, 2021, 81, 4275-4289.	0.4	9

#	Article	IF	Citations
109	Resistance mechanisms to taxanes and PARP inhibitors in advanced prostate cancer. Current Opinion in Endocrine and Metabolic Research, 2020, 10, 16-22.	0.6	8
110	Niclosamide in combination with abiraterone and prednisone in men with castration-resistant prostate cancer (CRPC): initial results from a phase Ib/II trial.. Journal of Clinical Oncology, 2018, 36, 192-192.	0.8	8
111	Transcriptional regulation of human RANK ligand gene expression by E2F1. Biochemical and Biophysical Research Communications, 2008, 370, 440-444.	1.0	6
112	Wntless promotes cellular viability and resistance to enzalutamide in castration-resistant prostate cancer cells. American Journal of Clinical and Experimental Urology, 2019, 7, 203-214.	0.4	6
113	Olaparib-Induced Senescence Is Bypassed through G2â€“M Checkpoint Override in Olaparib-Resistant Prostate Cancer. Molecular Cancer Therapeutics, 2022, 21, 677-685.	1.9	6
114	The Nâ€terminal kinase suppressor of Ras complex has a weak nucleoside diphosphate kinase activity. Thoracic Cancer, 2010, 1, 109-115.	0.8	3
115	RhoGDIÎ± downregulates androgen receptor signaling in prostate cancer cells. Prostate, 2013, 73, 1614-1622.	1.2	3
116	Stat5a/b in Prostate Cancer Metastasis. American Journal of Pathology, 2015, 185, 2351-2353.	1.9	3
117	A proteomic approach to elucidate the multiple targets of seleniumâ€induced cellâ€growth inhibition in human lung cancer. Thoracic Cancer, 2011, 2, 164-178.	0.8	2
118	The Roles of Homeobox Genes in Prostate Cancer. Prostate Journal, 1999, 1, 61-67.	0.2	0
119	NF-kappaB2/p52 in Prostate Cancer. , 2013, , 257-273.		0
120	Zoledronic acid at the time of castration prevented castration-induced bone metastasis in mice. Endocrine-Related Cancer, 2014, 21, C11-C14.	1.6	0
121	In honor of Dr. Donald S. Coffey â€“ Prostate cancer biology and therapy. Asian Journal of Urology, 2019, 6, 1-2.	0.5	0
122	STAT Signaling and Cell Function. Current Genomics, 2002, 3, 413-423.	0.7	0
123	Dysregulated androgen synthesis and anti-androgen resistance in advanced prostate cancer. American Journal of Clinical and Experimental Urology, 2021, 9, 292-300.	0.4	0